PEA-15 (D110) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
PEA-15 (D110) Peptide Applications :
Blocking Background :
PEA-15 (phosphoprotein enriched in astrocytes) exists in an non-phosphorylated form (N), and two phosphorylated forms, Pa and Pb. PEA-15 is an endogenous substrate for PKC, which mediates the transition from Pa to Pb. The level of PEA-15 phosphorylation changes upon depolymerization or stabilization of tubulins, indicating that PEA-15 co-localizes with microtubules. The first 80 amino acids of PEA-15 correspond to the death effector domain (DED), which is a domain found in proteins that regulate apoptotic signaling pathways. The DED domain is necessary for PEA-15 to block Ras suppression. Although PEA-15 is predominantly expressed in the central nervous system, low levels of PEA-15 are expressed in liver and kidney, and higher levels in muscle.PEA-15 is also referred to as PED, phosphoprotein enriched in diabetes, for its elevated expression in type 2 diabetic patients Alternative Name :
PEA15 (phospho S116); Phosphoprotein enriched in diabetes; PED; PEA15; HMAT1; HUMMAT1H; MAT1; MAT1H; PEA 15; PED Swiss-Prot :
Q15121 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide PEA-15 (D110). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS1573 PEA-15 (D110) pAb.
PEA-15 (D110) Peptide Applications :
Blocking Background :
PEA-15 (phosphoprotein enriched in astrocytes) exists in an non-phosphorylated form (N), and two phosphorylated forms, Pa and Pb. PEA-15 is an endogenous substrate for PKC, which mediates the transition from Pa to Pb. The level of PEA-15 phosphorylation changes upon depolymerization or stabilization of tubulins, indicating that PEA-15 co-localizes with microtubules. The first 80 amino acids of PEA-15 correspond to the death effector domain (DED), which is a domain found in proteins that regulate apoptotic signaling pathways. The DED domain is necessary for PEA-15 to block Ras suppression. Although PEA-15 is predominantly expressed in the central nervous system, low levels of PEA-15 are expressed in liver and kidney, and higher levels in muscle.PEA-15 is also referred to as PED, phosphoprotein enriched in diabetes, for its elevated expression in type 2 diabetic patients Alternative Name :
PEA15 (phospho S116); Phosphoprotein enriched in diabetes; PED; PEA15; HMAT1; HUMMAT1H; MAT1; MAT1H; PEA 15; PED Swiss-Prot :
Q15121 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide PEA-15 (D110). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS1573 PEA-15 (D110) pAb.
Blocking peptide available as BS1573PP